After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?

Marc Stapley, CEO of the genomic diagnostics company Veracyte (NASDAQ: VCYT), is enthusiastic about Rebecca Chambers, the new Chief Financial Officer (CFO), who started her role on July 19.

Stapley said he "can think of no one more qualified to lead our financial organization." Chambers' background includes a number of financial management roles with peer company, Illumina (NASDAQ: ILMN), and most recently as CFO with medical technology company, Outset Medical (NASDAQ: OM). So I believe that Stapley's ringing endorsement is sincere. But do his words of praise make Veracyte a buy? 

Image source: Getty Images.

Continue reading

Source Fool.com